Outcome of second allogeneic hematopoietic cell transplantation in adult patients with relapsed B-cell acute lymphoblastic leukemia in the era of new immunotherapeutic agents



Summary

This study investigates the effectiveness of second allogeneic hematopoietic cell transplantation (allo-HCT) for adult patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL) in the modern era of immunotherapy. It examines whether the improved outcomes from novel agents like blinatumomab and inotuzumab ozogamicin translate to better results after a second transplant. The analysis focuses on factors influencing survival, graft-versus-host disease, and relapse, aiming to identify patient populations who might benefit most from this aggressive approach following relapse despite prior transplant and potentially immunotherapy exposure. Ultimately, the research seeks to optimize treatment strategies for relapsed B-ALL patients eligible for a second allo-HCT.

Read more…

This post is part of “Science/Immunology News”, Follow for more…!!!